Brain-derived proteins in the CSF, do they correlate with brain pathology in CJD?

BMC Neurology

Volumn 6, Issue , 2006, Pages

  Boesenberg Grosse, Constanze ^a   Schulz Schaeffer, Walter J ^a   Bodemer, Monika ^a   Ciesielczyk, Barbara ^a   Meissner, Bettina ^a   Krasnianski, Anna ^a   Bartl, Mario ^a   Heinemann, Uta ^a   Varges, Daniela ^a   Eigenbrod, Sabina ^b   Kretzschmar, Hans A ^b   Green, Alison ^c   Zerr, Inga ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEURON SPECIFIC ENOLASE; PRION PROTEIN; PROTEIN 14 3 3; PROTEIN S100B; TAU PROTEIN;

ADULT; AGED; ARTICLE; BRAIN CORTEX LESION; CEREBROSPINAL FLUID ANALYSIS; CREUTZFELDT JAKOB DISEASE; DISEASE SEVERITY; FEMALE; GLIOSIS; HUMAN; INJURY SEVERITY; MAJOR CLINICAL STUDY; MALE; NERVE INJURY; NEUROPATHOLOGY; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DEFECT; PROTEIN LOCALIZATION; TISSUE DISTRIBUTION;

14-3-3 PROTEINS; ADULT; AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; BRAIN; CREUTZFELDT-JAKOB SYNDROME; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; PHOSPHOPYRUVATE HYDRATASE; PRIONS; S100 PROTEINS; TAU PROTEINS;

EID: 33749526682     PISSN: 14712377     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-6-35     Document Type: Article

References (39)

1. Hsich G, Kenney K, Gibbs Jr. CJ, Lee KH, Harrington MG: The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongifrom encephalopathies. N Engl J Med 1996, 335(13):924-930.
2. Zerr I, Bodemer M, Gefeller O, Otto M, Poser S, Wiltfang, Windl O, Kretzschmar HA, Weber T: Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt Jakob disease. Ann Neurol 1998, 43(1):32-40.
3. Green AJ: Use of 4-3-3 in the diagnosis of Creutzfeldt-Jakob disease. Biochem Soc Symp 2002, 30:382-386.
4. Kohira I, Tsuji T, Ishizu H, Takao Y, Wake A, Abe K, Kuroda S: Elevation of neuron-specific enolase in serum and cerebrospinal fluid of early stage Creutzfeldt-jakob disease. Acta Neurol Scand 2000, 102:385-387.
5. Van Everbroeck B, Green A, Pais P, Martin JJ, Cras P: Decreased levels of amyloid-beta 1-42 in cerebrospinal fluid of Creutzfeldt-Jakob disease patients. J Alzheimers Dis 1999, 1:419-424.
6. Van Everbroeck B, Green A, Vanmechelen E, Vanderstichele H, Pals P, Sanchez-Valle R, Corrales NC, Martin JJ, Cras P: Phosphorylated tau in cerebrospinal fluid as a marker for Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2002, 73:79-81.
7. Otto M, Esselmann H, Schulz-Schaeffer W, Neumann M, Schröter A, Ratzka P, Cepek L, Zerr I, Steinacker P, Windl O, Kornhuber J, Kretzschmar HA, Poser S, Wiltfang J: Decreased beta-amyloid 142 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology 2000, 54(5):1099-1102.
8. Van Everbroeck B, Boons J, Cras P: Cerebrospinal fluid biomarkers in Creutzfeldt-Jakob disease. Clin Neurol Neurosurg 2005, 107:355-360.
9. Van Everbroeck BR, Boons J, Cras P: 14-3-3 gamma-isoform detection distinguishes sporadic Creutzfeldt-Jakob disease from other dementias. J Neurol Neurosurg Psychiatry 2005, 76:100-102.
10. Piubelli C, Fiorini M, Zanusso G, Milli A, Fasoli E, Monaco S, Righetti PG: Searching for markers of Creutzfeldt-Jakob disease in cerebrospinal fluid by two-dimensional mapping. Proteomics 2006, 6 Suppl 1 :256-261.
11. Goodall CA, Head MW, Everington D, Ironside JW, Knight RS, Green AJ: Raised CSF phospho-tau concentrations in variant Creutzfeldt-Jakob disease: diagnostic and pathological implications. J Neurol Neurosurg Psychiatry 2006, 77:89-91.
12. Van Everbroeck B, Quoilin S, Boons J, Martin JJ, Cras P: A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2003, 74:1210-1214.
13. Jimi T, Wakayama Y, Shibuya S, Nakata H, Tomaru T, Takahashi Y, Kosaka K, Asano T, Kato K: High levels of nervous system-specific proteins in cerebrospinal fluid in patients with early stage Creutzfeldt-Jakob disease. Clin Chim Acta 1992, 211 (1-2):37-46.
14. Brandell JP, Peoc'h K, Beaudry P, Welaratne A, Bottos C, Agid Y, Laplanche JL: 14-3-3 protein cerebrospinal fluid detection in human growth hormone-treated Creutzfeldt-Jakob disease patients. Ann Neurol 2001, 49(2):257-260.
15. Kropp S, Zerr I, Schulz-Schaeffer WJ, Riedemann C, Bodemer M, Laske C, Kretzschmar HA, Poser S: Increase of neuron-specific enolase in patients with Creutzfeldt-Jakob disease. Neurosci Lett 1999, 261:124-126.
16. Mollenhauer B, Serafin S, Zerr I, Steinhoff BJ, Otto M, Scherer M, Schul-Schaeffer W, Poser S: Diagnostic problems during late course in Creutzfeldt-Jakob disease. J Neurol 2003, 250:629-630.
17. Zerr I, Pocchiari M, Collins S, Brandell JP, de Pedro Cuesta J, Knight RSG, Bernheimer H, Cardone F, Delasnerie-Lauprêtre N, Cuadrado Corrales N, Ladogana A, Fletcher A, Bodemer M, Awan T, Ruiz Bremón A, Budka H, Laplanche JL, Will RG, Poser S. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 2000, 55:811-815.
18. WHO: Human transmissible spongiform encephalopathies. Weekly Epidemiological Record 1998, 47:361-365.
19. Poser S, Mollenhauer B, Krauss A, Zerr I, Steinhoff BJ, Schröter A, Finkenstaedt M, Schulz-Schaeffer W, Kretzschmar HA, Felgenhauer K: How to improve the clinical diagnosis of Creutzfeldt-Jakob disease. Brain 1999, 122:2345-2351.
20. Windl O, Giese A, Schulz-Schaeffer W, Zerr I, Skworc K, Arendt S, Oberdieck C. Bodemer M, Poser S, Kretzschmar HA: Molecular genetics of human prion diseases in Germany. Hum Genet 1999, 105:244-252.
21. Parchi P, Castellani R, Capellari S, Ghetti B, Young K, Chen SG, Farlow M, Dickson DW, Sima AAF, Trojanowski JQ, Petersen RB, Gambetti P: Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol 1996, 39(6):767-778.
22. Parchi P, Giese A, Capellari S, Brown P, Schulz-Schaeffer W, Windl O, Zerr I, Budka H, Kopp N, Piccardo P, Poser S, Rojiani A, Streichemberger N. Julien J, Vital C, Ghetti B, Gambetti P, Kretzschmar HA: Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999, 46:224-233.
23. Otto M, Wiltfang J, Cepek L, Neumann M, Mollenhauer B, Steinacker P, Ciesielczyk B, Schulz-Schaeffer W, Kretzschmar HA, Poser S: Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2002, 58:192-197.
24. Otto M, Stein H, Szudra A, Zerr I, Bodemer M, Gefeller O, Poser S, Kretzschmar HA, Maeder M, Weber T: S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurol 1997, 244(9):566-570.
25. Zerr I, Bodemer M, Kaboth U, Kretzschmar H, Oellerich M, Armstrong VW. Plasminogen activities and concentrations in patients with sporadic Creurtzfeldt-Jakob disease. Neurosci Lett 2004, 371:163-166.
26. Peoc'h K, Schroder HC, Laplanche J, Ramijak S, Muller WE. Determination of 14-3-3 protein levels in cerebrospinal fluid from Creutzfeldt-Jakob patients by a highly sensitive capture assay. Neurosci Lett 2001, 301(3):167-170.
27. Volkell D, Zimmermann K, Zerr I, Bodemer M, Lindner T, Turecek PL, Poser S, Schwarz HP: Immunochemical determination of cellular prion protein in plasma from healthy subjects and patients with sporadic CJD or other neurologic diseases. Transfusion 2001, 41(4):441-448.
28. Green AJ, Thompson EJ, Stewart GE, Zeidler M, McKenzie JM, MacLeod MA, Ironside JW, Will RG, Knight RS: Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2001, 70:744-748.
29. Geschwind M, Martindale J, Miller D, De Armond SJ, Uyehara-Lock J, Gaskin D, Kramer JH, Barbaro NM, Miller BL: Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease. Arch Neurol 2003, 60:813-816.
30. Burkhard PR, Sanchez JC, Landis T, Hochstrasser DF: CSF detection of the 14-3-3 protein in unselected patients with dementia. Neurology 2001, 56(11):1528-1533.
31. Schaarschmidt H, Prange HW, Reiber H: Neuron-specific enolase concentration in blood as a prognostic parameter in cerebrovascular diseases. Stroke 1994, 25:558-565.
32. Wunderlich MT, Wallesch CW, Goetler M: Release of neurobiochemical markers of brain damage is related to the neurovascular status on admission and the site of arterial occlusion in acute ischemic stroke. J Neurol Sci 2004, 227:49-53.
33. Riemenschneider M, Wagenpfeil S, Vanderstichele H, Otto M, Wiltfang J, Kretzschmar H, Vanmechelen E, Förstl H, Kurz A: Phosphotau/total tau ration in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Molecular Psychiatry 2003, 8:343-347.
34. Andreasen N, Minthon L, Clarberg A, Davidson P, Gottfries; J, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K: Sensitivity, specificity and stability of CSF-tau in AD in a community based patient sample. Neurology 1999, 7:1488-1494.
35. Grossman M, Farmer J, Leight S, Work M, Moore P, Van Deerlin V, Pratico D, Clark CM, Branch Coslett H, Chatterjee A, Gee J, Trojanowski JQ, Lee M: Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann Neurol 2005, 57(5):721-729.
36. Castellani RJ, Colucci M, Xie Z, Zou W, Li C, Parchi P, Capellari S, Pastore M, Rahbar MH, Chen SG, Gambetti P: Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creurtzfeldt-Jakob disease. Neurology 2004, 63:436-442.
37. Chen XQ, Fung YW, Yu AC: Association of 14-3-3 gamma and phosphorylated bad attenuates injury in ischemic astrocytes. J Cereb Blood Row Metab 2005, 25:338-347.
38. Kawamoto Y, Akiguchi I, Jarius C, Budka H: Enhanced expression of 14-3-3 proteins in reactive astrocytes in Creutzfeldt-Jakob disease brains. Acta Neuropathol (Berl) 2004, 108:302-308.
39. Jansen GH, Vogelaar CF. Elshof SM: Distribution of cellular prion protein in normal human cerebral cortex - does it have relevance to Creutzfeldt-Jakob disease? Clin Chem Lab Med 2001, 39(4):294-298.